Longitudinal Outpatient Treatment for Cannabis Use Disorder
Status:
Recruiting
Trial end date:
2029-03-31
Target enrollment:
Participant gender:
Summary
This study is a placebo-controlled randomized trial comparing the effects of hemp-derived
cannabidiol (CBD) with and without Delta-9-tetrahydrocannabinol (THC), relative to placebo,
on reducing cannabis use and cannabis use disorder (CUD) symptoms in adult treatment seeking
cannabis concentrate users with CUD. Participants enroll in the study for 8 weeks (with
telehealth follow-ups at 12 and 16 weeks) and are randomized to either full spectrum CBD,
broad spectrum CBD, or placebo. Participants are also engaged in five weeks of psychotherapy
treatment for CUD. Blood is collected to quantify investigational drug exposure and cannabis
use. Participants also complete self-report measures of medical history, sleep quality,
subjective cognitive function, physical activity, psychological functioning, substance use,
and acute drug effects.